Enoxaparin
Thrombophlebitis
University Of Perugiaother_biologicalPhase 3Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Thrombophlebitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
WARFARIN Massachusetts General Hospital | Phase 3 | BB |
Heparin Johns Hopkins University | Phase 4 | B |
FONDAPARINUX Johns Hopkins University | Early Phase 1 | CC |
Same molecule, other indications
Enoxaparin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →